Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) is a publicly traded Healthcare sector company. As of July 10, 2026, RANI trades at $0.71 with a market cap of $77.89M and a P/E ratio of -2.40. RANI moved +0.35% today. Year to date, RANI is -48.28%; over the trailing twelve months it is +5.64%. Its 52-week range spans $0.39 to $3.87. Analyst consensus is strong buy with an average price target of $7.50. Rallies surfaces RANI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rani Therapeutics Partners with PegBio to Formulate Multiple Oral Obesity Candidates via RaniPill: Rani Therapeutics will collaborate with PegBio to develop RaniPill oral formulations for multiple obesity and metabolic disease candidates, advancing selected molecules into preclinical and potential clinical stages. This partnership expands Rani’s obesity franchise beyond its RT-114 GLP-1/GLP-2 Phase 1 trial and preclinical semaglutide program, adding new mechanisms of action.
| Metric | Value |
|---|---|
| Price | $0.71 |
| Market Cap | $77.89M |
| P/E Ratio | -2.40 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.87 |
| 52-Week Low | $0.39 |
| Volume | 500.85K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.17M |
| Net Income | $-36.23M |
| Gross Margin | 0.00% |
4 analysts cover RANI: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.50.